[Combination chemotherapy with Hemzar (gemcitabine) and cisplatin for relapsing and cisplatin-resistant ovarian cancer].
The paper is concerned with the data on treatment of 33 patients with advanced ovarian cancer, aged 34-72 (average age of 52.5). Having received numerous regimens of combination chemotherapy, mainly, with cisplatin-containing drugs, sixty-one percent had visceral metastases. Early-onset relapse was in 18.2%, late-onset--12.1% and primary refractory to cisplatin chemotherapy--30%. Hemzar (hemcytabin) + cisplatin + carboplatin treatment was given in 15- or 8-day courses (hemzar--1,000 mg/m2, day 1, 8 and 15 or day 1 and 8; cisplatin m2 or carboplatin AVC5--60 mg/m2, day 1 or 15, day 1 or 8, respectively). A total of 102 cycles of therapy were given and evaluated. Complete response was reported in 2 (6.0%), partial--5 (15.2%), and stabilization--13 (39.4%); significant clinical effect--60.6%. Such side-effects as leukemia stage I-II--63.6%; stage III-IV--3%, neutropenia stage I-II--39.4; stage III-IV--24.2%, thrombocytopenia stage I-II--6%, and asthenia stage I-II--12.1%, stage III-IV--3 patients, did not interfere with treatment. Combination chemotherapy with hemzar + cisplatin + carboplatin was effective and sufficiently tolerable. It is indicated in management of relapse and primary resistance to cisplatin drugs administered for ovarian cancer whenever all other remedies have failed.
Makhnova
E V
EV
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D012008:Recurrence; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine
Kombinirovannaia khimioterapiia gemzarom (gemtsitabinom) i preparatami platiny pri retsidivakh i platinorezistentnykh formakh raka iaichnikov.